{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T06:45:42Z","timestamp":1697352342005},"reference-count":42,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,12,18]],"date-time":"2009-12-18T00:00:00Z","timestamp":1261094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cinacalcet efficacy is limited in severe secondary hyperparathyroidism (SHPT) and its effect on parathyroid gland (PTG) volume and morphology have not been sufficiently investigated. We evaluated the effect of cinacalcet treatment for one year on the laboratory parameters of calcium\u2013phosphorus metabolism and PTG ultrasound (US) patterns in hemodialysis (HD) patients with severe SHPT and US results indicative of nodular hyperplasia. Thirteen HD patients with severe SHPT (intact parathyroid hormone &gt;700\u2003pg\/mL), US\/scintigraphic evidence of at least one PTG with a diameter &gt;7\u2003mm, and high surgical risk or refusal of surgery were included. The patients were treated with cinacalcet. The initial dose of 30\u2003mg was increased up to 180\u2003mg once daily. At baseline and after one year of cinacalcet treatment a neck US was performed, providing data on 22 parathyroid glands in eight patients. The mean diameter at baseline and at one year was 12.6\u2003\u00b1\u20035.9 and 13.0\u2003\u00b1\u20035.3\u2003mm, respectively (<jats:italic>P<\/jats:italic>\u2003=\u20030.46). Similarly, the mean volume at baseline and at one year was 513.4\u2003\u00b1\u2003416.3 and 556.8\u2003\u00b1\u2003480.8\u2003mm<jats:sup>3<\/jats:sup>, respectively (<jats:italic>P<\/jats:italic>\u2003=\u20030.18). The US structural score remained unchanged in 16 parathyroid glands and increased in 6 (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.03), while the vascular score remained unchanged in 16 parathyroid glands and decreased in 6 (<jats:italic>P<\/jats:italic>\u2003=\u20030.25). Thus it can be concluded that cinacalcet treatment for one year in HD patients with severe SHPT is not associated with significant changes in parathyroid gland US patterns.<\/jats:p>","DOI":"10.1111\/j.1744-9987.2009.00781.x","type":"journal-article","created":{"date-parts":[[2009,12,18]],"date-time":"2009-12-18T12:08:14Z","timestamp":1261138094000},"page":"178-185","source":"Crossref","is-referenced-by-count":9,"title":["Parathyroid Gland Ultrasound Patterns and Biochemical Findings After One\u2010year Cinacalcet Treatment for Advanced Secondary Hyperparathyroidism"],"prefix":"10.1111","volume":"14","author":[{"given":"Carlo","family":"Vulpio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Bossola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"De Gaetano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Maresca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Di Stasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Zagaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Castagneto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,3,26]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000133041.27682.A2"},{"key":"e_1_2_6_3_2","first-page":"1830","article-title":"Chronic kidney disease\u2010mineral\u2010bone disorder: a new paradigm","volume":"17","author":"Moe SM","year":"2007","journal-title":"Clin Calcium"},{"issue":"3","key":"e_1_2_6_4_2","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(04)01103-5"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001594"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1774-9987.2005.00213.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2005.00302.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116720"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1480403"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2008.00648.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767140-00003"},{"key":"e_1_2_6_13_2","first-page":"1981","article-title":"Paricalcitol in dialysis patients with calcitriol\u2010resistant secondary hyperparathyroidism","volume":"67","author":"Llach F","year":"2007","journal-title":"Drugs"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002428"},{"key":"e_1_2_6_15_2","first-page":"767","article-title":"Mortality risk among hemodialysis patients receiving different vitamin D analogs","volume":"17","author":"Tentori F","year":"2007","journal-title":"Clin Calcium"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00302.2004"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119851"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman WG","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.06.019"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031633"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004060512"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000050224.03126.AD"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.67139.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00596.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn026"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03591006"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2005.00476.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2008.00627.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199008093230617"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1994.223"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg1009"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2008.00615.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000116875"},{"key":"e_1_2_6_34_2","first-page":"67","article-title":"Basic and clinical aspects of calcimimetics. Calcimimetic is indicated for patients with surgically uncontrollable hyperparathyroidism","volume":"18","author":"Tominaga Y","year":"2008","journal-title":"Clin Calcium"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.03.009"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2007.13.5.397"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl774"},{"key":"e_1_2_6_38_2","unstructured":"National Institute for Health and Clinical Excellence (NICE).Cinacalcet for the treatment of secondary hyperthyroidism in patients with end\u2010stage renal disease on maintenance dialysis therapy. NICE Technology Appraisal Guidance 117. January2007:4\u201327."},{"key":"e_1_2_6_39_2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1681\/ASN.V115903","article-title":"Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats","volume":"11","author":"Chin J","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.67103.x"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118224"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn579"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm177"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1744-9987.2009.00781.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1744-9987.2009.00781.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T13:59:30Z","timestamp":1697291970000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1744-9987.2009.00781.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,26]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1111\/j.1744-9987.2009.00781.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1744-9987.2009.00781.x","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,26]]}}}